echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Domestic pharmaceutical industry accelerates reshuffle, business executives frequently "go away"

    Domestic pharmaceutical industry accelerates reshuffle, business executives frequently "go away"

    • Last Update: 2020-11-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "Pharmaceutical Network Market Analysis" in the consistent evaluation, medical insurance catalog adjustment, volume procurement and other policies, coupled with the impact of this year's special period, the domestic pharmaceutical industry is accelerating the reshuffle.
    , the drug terminal market fell sharply in the first quarter of 2020, according to new data released by Zhongkang CMH.
    china's drug market is expected to be about 1.78 trillion yuan in full 2020, down 2.3 percent from 2019, with a rare negative growth.
    background, the pharmaceutical industry in the past "lying on the money era" is gone, industrial restructuring accelerated, will be in the direction of innovation transformation and upgrading.
    , the traditional marketing model and the composition of the sales team of pharmaceutical companies are also beginning to change, and the competition for talent in the industry is becoming more intense.
    According to incomplete statistics in the industry, in early August alone, a number of pharmaceutical listed company executives announced their resignations, including Step Pharmaceuticals, Fish Leap Medical, Tonghua Dongbao, etc.;
    , according to relevant statistics, so far this year, in 2019 revenue of more than 100 million yuan of listed pharmaceutical companies, more than 69 enterprises have been personnel changes.
    among them, Fosun Pharma, Northeast Pharmaceuticals, Jiuzhitang, Dongcheng Pharmaceuticals, Jiangsu Wu Zhong, Lisheng Pharmaceuticals 6 pharmaceutical company executives left the number of 4 or more people.
    it is learned that in half a year, nine Shitang staff in succession six executives "out", Fosun Pharma changes are also more frequent, the first half of the "out" of five executives.
    not only domestic pharmaceutical companies, multinational pharmaceutical companies are also frequently staged personnel changes.
    August 19th, the industry broke the news that Luo Yongqing, Gilead's global vice president and general manager of China, had decided to leave the company and seek external development.
    China said the company's day-to-day operations are business as usual, the recruitment of a new general manager has been started.
    In June, Duan Xiaoxuan, former PRESIDENT and CEO of GE International Business, announced his resignation; in May, Guo Anfeng, Vice President of BMS China Oncology Division, joined 1 Pharmaceutical Network as the first Innovation Officer;
    and whether it is local pharmaceutical companies or multinational pharmaceutical enterprises, the series of "departure tide" behind, and the domestic pharmaceutical market environment changes closely.
    days ago, the third batch of national tenders, a total of 189 enterprises to participate in the election of 125 enterprises, the proposed drug selection rules 191, the average price reduction of 53%, to a high decline of 95%. . . . This series of figures are pointing to the collection, generic drug market will enter the era of micro-profit, innovation can have a future.
    in the industry's view, the current pharmaceutical companies whether it is business adjustment or market reshuffle, talent has always been the core element.
    business adjustment of multinational pharmaceutical companies will continue to trigger a talent war in China's pharmaceutical market, and cooperation and competition with local pharmaceutical companies will become more intense.
    According to the relationship between the industrial development environment and performance pressure, industry insiders expect that there will be more frequent changes in the top executives of seven types of enterprises in the future, including: marketing enterprises based on a single cost, integrated enterprises based on capital mergers and acquisitions, opportunity enterprises based on public relations, enterprises pricing long-term windfall profits based on research and development advantages, investment enterprises based on simple benefit distribution, enterprises with rapid concentration in the professional field, and enterprises with excessive superstition and tactical neglect of strategic research.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.